• The Journal of Korean Obstetrics and Gynecology
• /
• v.21 no.2
• /
• pp.284-291
• /
• 2008

Purpose: The purpose of this study is to report the effect of oriental treatments for PCOD(Polycystic Ovarian Disease) patient with amenorrhoea. Methods: A 24 years old women, who diagnosed PCOD(Polycystic Ovarian Disease), was enrolled in this study. She received oriental treatments such as herbal medicine, acupuncture for 5 months. And we proceeded to checkup female hormone regularly, such as Estrogen, Progesteron, LH, FSH, Prolactin, testosterone. We observed the menstruation period and figure out LH/FSH ratio. Results: 1. We treated PCOD patient with oriental herbal medicine(Changbudodamtang) and acupuncture. 2. PCOD patient restart menstruation regularly. 3. PCOD patient's LH/FSH ratio decreased. 4. PCOD patient's testosterone was within normal limit. Conclusion: 1. We treated PCOD patient with oriental herbal medicine(Changbudodamtang) and acupuncture, and then PCOD patient restart menstruation regularly. 2. We treated PCOD patient with oriental herbal medicine(Changbudodamtang) and acupuncture, and then we observed that LH/FSH ratio decreased.

• Clinical and Experimental Reproductive Medicine
• /
• v.27 no.2
• /
• pp.151-157
• /
• 2000

Objective: The purpose of this study was to evaluate the effect of polycystic ovarian follicular fluid on sperm motility in human in vitro fertilization (IVF). Methods: From May, 1998 to July, 1999, 55 patients who complained of infertility were involved in this study. We obtained ovarian follicular fluids from the patients by ultrasono-guided aspiration. Subjects were divided into two groups. 20 patients who had polycystic ovarian disease were belong to study group, and 25 patients who had normal ovarian follicular fluid were belong to control group. The follicular fluid dilution was done with Ham's fluid as 10%, 20%, 50%, 100%. The sperm motility was analyzed by CASA at 6hr and 12hr after incubation in follicular fluids. Results: The levels of average path velocity (VAP) in all concentration fluid didn't show significant difference between study and control group. The other parameters including curvilinear velocity (VCL), amplitude of lateral head displacement (ALH), and linerity (LIN) were didn't show any significant difference between both groups. Conclusion: PCOD fluid had seemed to have an adverse effect on the sperm biological function. But, this study showed that PCOD fluid had no different effect on sperm motility with normal follicular fluid.

• CELLMED
• /
• v.12 no.3
• /
• pp.10.1-10.12
• /
• 2022

Objective: The objective of the study was to evaluate the effect of Sharbat Afsantin in Polycystic Ovarian Disease. Methods: An open observational study was carried out in the Department of Ilmul Qabalat wa Amraze Niswan. Diagnosed cases(n=30) of PCOD were included in the study. Patients with thyroid dysfunction, systemic diseases, on hormonal treatment in last three months, pregnancy and lactation were excluded. Research drug (Sharbat Afsantin) was administered orally in a dose of 25ml twice daily for 15 days/cycle for three consecutive cycles. Outcome measures were, changes in subjective parameters (duration of cycle, duration and amount of flow and weight reduction) and objective parameters {pictorial blood loss assessment chart (PBAC) score, basal metabolic index (BMI), modified Ferriman Gallwey (mFG) score, acanthosis nigricans scale and pelvic ultrasonography}. Data were analyzed using paired Student 't' test. Results: Changes in duration of cycle, duration and amount of flow were achieved in 83.3%, 50% and 40% patients respectively and weight reduction in 30% patients. Changes in PBAC score and BMI were achieved in 50% and 30% patients respectively and 30% patients showed normal findings on pelvic ultrasonography. Conclusion: Sharbat Afsantin can be used as an alternate remedy in PCOD patients, as it has significant effect to regularize menstruation by reduction in BMI and probably by improving insulin resistance in PCOD. No adverse effect of Sharbat Afsantin was noted during the trial.